1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Ophthalmic Drug CDMO Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Ophthalmic Drug CDMO Market, by Service Type
8.1.1. Drug Substance Development & Manufacturing
8.1.1.1. Market Revenue and Forecast
8.1.2. Drug Product Manufacturing (Formulation & Fill-Finish)
8.1.2.1. Market Revenue and Forecast
8.1.3. Packaging & Labelling
8.1.3.1. Market Revenue and Forecast
8.1.4. Analytical & Regulatory Services
8.1.4.1. Market Revenue and Forecast
9.1. Ophthalmic Drug CDMO Market, by Dosage Form
9.1.1. Eye Drops & Solutions
9.1.1.1. Market Revenue and Forecast
9.1.2. Ointments & Gels
9.1.2.1. Market Revenue and Forecast
9.1.3. Emulsions & Suspensions
9.1.3.1. Market Revenue and Forecast
9.1.4. Inserts & Implants
9.1.4.1. Market Revenue and Forecast
10.1. Ophthalmic Drug CDMO Market, by Molecule Type
10.1.1. Small Molecules
10.1.1.1. Market Revenue and Forecast
10.1.2. Biologics
10.1.2.1. Market Revenue and Forecast
11.1. Ophthalmic Drug CDMO Market, by Therapeutic Area
11.1.1. Biologics
11.1.1.1. Market Revenue and Forecast
11.1.2. Dry Eye Disease
11.1.2.1. Market Revenue and Forecast
11.1.3. Retinal Disorders (AMD, DME, etc.)
11.1.3.1. Market Revenue and Forecast
11.1.4. Eye Infections & Allergies
11.1.4.1. Market Revenue and Forecast
11.1.5. Others
11.1.5.1. Market Revenue and Forecast
12.1. Ophthalmic Drug CDMO Market, by End User
12.1.1. Large Pharmaceutical Companies
12.1.1.1. Market Revenue and Forecast
12.1.2. Biotechnology Firms
12.1.2.1. Market Revenue and Forecast
12.1.3. Specialty Ophthalmic Companies
12.1.3.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Service Type
13.1.2. Market Revenue and Forecast, by Dosage Form
13.1.3. Market Revenue and Forecast, by Molecule Type
13.1.4. Market Revenue and Forecast, by Therapeutic Area
13.1.5. Market Revenue and Forecast, by End User
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Service Type
13.1.6.2. Market Revenue and Forecast, by Dosage Form
13.1.6.3. Market Revenue and Forecast, by Molecule Type
13.1.6.4. Market Revenue and Forecast, by Therapeutic Area
13.1.6.5. Market Revenue and Forecast, by End User
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Service Type
13.1.7.2. Market Revenue and Forecast, by Dosage Form
13.1.7.3. Market Revenue and Forecast, by Molecule Type
13.1.7.4. Market Revenue and Forecast, by Therapeutic Area
13.1.7.5. Market Revenue and Forecast, by End User
13.2. Europe
13.2.1. Market Revenue and Forecast, by Service Type
13.2.2. Market Revenue and Forecast, by Dosage Form
13.2.3. Market Revenue and Forecast, by Molecule Type
13.2.4. Market Revenue and Forecast, by Therapeutic Area
13.2.5. Market Revenue and Forecast, by End User
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Service Type
13.2.6.2. Market Revenue and Forecast, by Dosage Form
13.2.6.3. Market Revenue and Forecast, by Molecule Type
13.2.7. Market Revenue and Forecast, by Therapeutic Area
13.2.8. Market Revenue and Forecast, by End User
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Service Type
13.2.9.2. Market Revenue and Forecast, by Dosage Form
13.2.9.3. Market Revenue and Forecast, by Molecule Type
13.2.10. Market Revenue and Forecast, by Therapeutic Area
13.2.11. Market Revenue and Forecast, by End User
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Service Type
13.2.12.2. Market Revenue and Forecast, by Dosage Form
13.2.12.3. Market Revenue and Forecast, by Molecule Type
13.2.12.4. Market Revenue and Forecast, by Therapeutic Area
13.2.13. Market Revenue and Forecast, by End User
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Service Type
13.2.14.2. Market Revenue and Forecast, by Dosage Form
13.2.14.3. Market Revenue and Forecast, by Molecule Type
13.2.14.4. Market Revenue and Forecast, by Therapeutic Area
13.2.15. Market Revenue and Forecast, by End User
13.3. APAC
13.3.1. Market Revenue and Forecast, by Service Type
13.3.2. Market Revenue and Forecast, by Dosage Form
13.3.3. Market Revenue and Forecast, by Molecule Type
13.3.4. Market Revenue and Forecast, by Therapeutic Area
13.3.5. Market Revenue and Forecast, by End User
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Service Type
13.3.6.2. Market Revenue and Forecast, by Dosage Form
13.3.6.3. Market Revenue and Forecast, by Molecule Type
13.3.6.4. Market Revenue and Forecast, by Therapeutic Area
13.3.7. Market Revenue and Forecast, by End User
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Service Type
13.3.8.2. Market Revenue and Forecast, by Dosage Form
13.3.8.3. Market Revenue and Forecast, by Molecule Type
13.3.8.4. Market Revenue and Forecast, by Therapeutic Area
13.3.9. Market Revenue and Forecast, by End User
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Service Type
13.3.10.2. Market Revenue and Forecast, by Dosage Form
13.3.10.3. Market Revenue and Forecast, by Molecule Type
13.3.10.4. Market Revenue and Forecast, by Therapeutic Area
13.3.10.5. Market Revenue and Forecast, by End User
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Service Type
13.3.11.2. Market Revenue and Forecast, by Dosage Form
13.3.11.3. Market Revenue and Forecast, by Molecule Type
13.3.11.4. Market Revenue and Forecast, by Therapeutic Area
13.3.11.5. Market Revenue and Forecast, by End User
13.4. MEA
13.4.1. Market Revenue and Forecast, by Service Type
13.4.2. Market Revenue and Forecast, by Dosage Form
13.4.3. Market Revenue and Forecast, by Molecule Type
13.4.4. Market Revenue and Forecast, by Therapeutic Area
13.4.5. Market Revenue and Forecast, by End User
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Service Type
13.4.6.2. Market Revenue and Forecast, by Dosage Form
13.4.6.3. Market Revenue and Forecast, by Molecule Type
13.4.6.4. Market Revenue and Forecast, by Therapeutic Area
13.4.7. Market Revenue and Forecast, by End User
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Service Type
13.4.8.2. Market Revenue and Forecast, by Dosage Form
13.4.8.3. Market Revenue and Forecast, by Molecule Type
13.4.8.4. Market Revenue and Forecast, by Therapeutic Area
13.4.9. Market Revenue and Forecast, by End User
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Service Type
13.4.10.2. Market Revenue and Forecast, by Dosage Form
13.4.10.3. Market Revenue and Forecast, by Molecule Type
13.4.10.4. Market Revenue and Forecast, by Therapeutic Area
13.4.10.5. Market Revenue and Forecast, by End User
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Service Type
13.4.11.2. Market Revenue and Forecast, by Dosage Form
13.4.11.3. Market Revenue and Forecast, by Molecule Type
13.4.11.4. Market Revenue and Forecast, by Therapeutic Area
13.4.11.5. Market Revenue and Forecast, by End User
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Service Type
13.5.2. Market Revenue and Forecast, by Dosage Form
13.5.3. Market Revenue and Forecast, by Molecule Type
13.5.4. Market Revenue and Forecast, by Therapeutic Area
13.5.5. Market Revenue and Forecast, by End User
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Service Type
13.5.6.2. Market Revenue and Forecast, by Dosage Form
13.5.6.3. Market Revenue and Forecast, by Molecule Type
13.5.6.4. Market Revenue and Forecast, by Therapeutic Area
13.5.7. Market Revenue and Forecast, by End User
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Service Type
13.5.8.2. Market Revenue and Forecast, by Dosage Form
13.5.8.3. Market Revenue and Forecast, by Molecule Type
13.5.8.4. Market Revenue and Forecast, by Therapeutic Area
13.5.8.5. Market Revenue and Forecast, by End User
14.1. Piramal Pharma Solutions
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Siegfried Holding AG
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Recipharm AB
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. BioPharma Solutions
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Vetter Pharma International
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Baxter BioPharma Solutions
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Ajinomoto Bio-Pharma Services
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Recipharm AB
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Thermo Fisher Scientific
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Alcami Corporation
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
